CanaQuest Medical Corp Overview
Comprehensive Solution for Epilepsy Drug Commercialization and a
Platform for Future Neurological Treatments
CanaQuest is a clinical-stage life sciences company positioned as the next “GW Pharma 2.0.” Guided by former GW Pharma executives Dr. Jordyn Stuart and Dr. Hunter Land—key figures behind Epidiolex’s $7.2B acquisition by Jazz Pharma—CanaQuest is advancing CQ-001, a patent-pending treatment for refractory epilepsy. With 35% improved efficacy over existing therapies, CQ-001 targets the 19.5 million patients globally affected by this severe condition. The company is pursuing FDA Orphan Drug Status, enabling seven years of market exclusivity post-approval.
CanaQuest has significantly de-risked CQ-001, positioning it for regulatory approval in Canada and the U.S. within 3-4 years. Leveraging the regulatory groundwork laid by GW Pharma’s Epidiolex, CQ001—a patent-pending cannabidiol formulation—packaged in a novel format that includes GRAScertified ingredients, including EPA and DHA, to enhance efficacy and minimize side effects. This innovative platform also unlocks potential applications in neurological and veterinary treatments.
• Regulatory Preparedness: New Drug Applications (NDAs) are to be completed for the FDA and Health Canada, targeting exclusivity through Orphan Drug Status.
• Experienced Team: Dr. Stuart and Dr. Land bring extensive cannabinoid and clinical trial expertise.
• Enhanced Efficacy: CQ-001 synergizes cannabidiol with EPA and DHA molecules via PPAR receptor activation for better outcomes.
• Global Manufacturing: Access to ISO 17025-certified facilities in North America, Europe, and India support scalability.
This foundation sets the stage for future treatments targeting neurological conditions such as depression, anxiety, and PTSD.
Accumulated Expertise
A world-class team to advance CQ-001 through regulatory approval and commercialization:
- Dr. Jordyn Stuart, Ph.D.: Cannabinoid expert with 12 years of research & consulted with physicians to launch and distribute Epidiolex®.
- Dr. Hunter Land, Ph.D.: Co-led Epidiolex clinical development and regulatory approval.
- Eddie Francis, MS: COO with molecular biology expertise.
- Dr. Paul Dick, DVM, MSc: Advisory Chair with 30+ years in pharma and animal health.
- Neil Kothari, J.D.: Fractional securities lawyer, Finance, IP, and licensing expert.
Market Opportunity Epilepsy affects 1.2% of the global population, with 30% suffering from refractory cases. Options like Epidiolex see a 25% patient discontinuation rate due to side effects. CQ-001’s enhanced efficacy and lower dosages aim to penetrate the serviceable addressable US $1.9B market.
Awards and Recognition CanaQuest has been awarded, Medical Cannabinoid Development Company of the Year 2024 and Endocannabinoid Therapeutics Development Company of the Year 2024 by Global Health & Pharma, UK in its ninth annual Healthcare and Pharmaceutical Awards.
Exit Strategy Our exit strategy includes an uplisting and a potential acquisition by a large pharmaceutical company. Jazz Pharma’s 7.2 billion acquisition of GW Pharma serves as a notable precedent.
Investment Opportunity Despite the challenges and risks associated with the regulatory approval process, CanaQuest’s comprehensive strategy, coupled with the expertise of its management and consultants, positions the company well to navigate the regulatory landscape and achieve its objectives, making it a compelling investment opportunity.
Investment Ask (two rounds) CanaQuest has a VC firm that has expressed interest in participating in a syndicate of up to $US 10 million to advance clinical trials, explore veterinary applications, and expand partnerships subject to CanaQuest securing a lead investor.
Contact: Paul Ramsay, CEO 416-704-3040 | paul@canaquest.com www.canaquest.com
Cautionary statement regarding forward-looking information:
This Overview contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on current expectations, estimates, forecasts, and projections about the industry in which CanaQuest Medical Corp operates and the beliefs and assumptions of the management of CanaQuest. Forward-looking statements may be identified by the use of forward-looking terminology such as “plans,” “expects,” “believes,” “estimates,” “intends,” “may,” “will,” “should,” “could,” “anticipates,” “predicts,” “potential,” “continue,” or similar terms, variations of those terms or the negative of those terms. The forward-looking statements include but are not limited to, statements regarding:
- The anticipated benefits and effectiveness of Drug Candidate, CQ-001, and its potential to treat rare neurological conditions of epilepsy.
- The expected progress and outcomes of clinical trials for CQ-001 and the nutraceutical formulation, Mentanine™.
- CanaQuest’s ability to navigate the regulatory approval process successfully.
- The potential for commercialization of cannabidiol-based pharmaceuticals and nutraceuticals.
- The impact of the executive team appointments on CanaQuest’s clinical trials and regulatory approval processes.
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions about CanaQuest Medical Corp, and there can be no assurance that the expectations of CanaQuest will be realized. Important factors that could cause actual results to differ materially from those in the forward-looking statements include:
- The possibility that clinical trials of CQ-001 may not be successful or may take longer than anticipated to complete.
- Challenges in securing regulatory approvals or changes in the regulatory environment.
- The potential for unforeseen side effects or other safety issues that could interrupt or halt clinical trials or affect patient enrollment.
- The ability to protect intellectual property and to operate without infringing upon the proprietary rights of others.
- Market acceptance of the Company’s products and competition from existing products or new products that may emerge.
- The impact of economic, competitive, governmental, technological, or other factors on the pharmaceutical and nutraceutical markets that could affect the Company’s operations or financial results.
- The company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated, and the results, cost, and timing of the company’s clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation, may not be as expected.
Investors are cautioned that any forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. CanaQuest Medical Corp undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Q1 2025